ResMed Inc. (RMD) — Analysis Summary
ResMed Inc. (RMD) has a market cap of $28.79B with year-over-year revenue growth of +9.8%. Net margin stands at 27.2%. The stock trades at a P/E ratio of 18.9.
Key Takeaways
- Revenue changed +9.8% year-over-year
- Net margin of 27.2%
- P/E ratio of 18.9
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, RMD posted revenue growth of +9.8% and trades at a P/E of 18.9.
ResMed Inc. (RMD)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
10,600
Headquarters
SAN DIEGO, CA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$2.40
Dividend Yield
1.24%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.